Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 52, Issue 15, Pages 4892-4902Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm900490a
Keywords
-
Categories
Funding
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases [AI069966]
- National Institute of General Medical Sciences [GM51670]
Ask authors/readers for more resources
N-{4-[(2-Amino-6-ethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)thio]benzoyl}-L-glutamic acid 2 and 13 nonclassical analogues 2a-2m were synthesized as potential dual thymidylate synthase (TS) and dihydrofolate reductase (DHFR) inhibitors and as antitumor agents. The key intermediate in the synthesis was 2-amino-6-ethyl-5-iodothieno[2,3-d]pyrimidin-4(3H)-one, 7, to which various arylthiols were attached at the 5-position. Coupling 8 with L-glutamic acid diethyl ester and saponification afforded 2. X-ray crystal structures of 2 and 1 (the 6-methyl analogue of 2), DHFR, and NADPH showed for the first time that the thieno[2,3-d]pyrimidine ring binds in a folate mode. Compound 2 was an excellent dual inhibitor of human TS IC50 = 54 nM) and human DHFR (IC50 = 19 nM) and afforded nanomolar GI(50) values against tumor cells in culture. The 6-ethyl substitution in 2 increases both the potency (by 2-3 orders of magnitude) as well as the spectrum of tumor inhibition in vitro compared to the 6-methyl analogue 1. Some of the nonclassical analogues were potent and selective inhibitors of DHFR from Toxoplasma gondii.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available